These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36813175)

  • 1. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
    Vendrely V; Lemanski C; Pommier P; LE Malicot K; Saint A; Rivin Del Campo E; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; Minsat M; Drouet F; Larrouy A; Peiffert D; Lievre A; Zasadny X; Hautefeuille V; Mornex F; Lepage C; Quero L;
    Radiother Oncol; 2023 Jun; 183():109542. PubMed ID: 36813175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of
    Combet-Curt V; Buchalet C; Le Malicot K; Lemanski C; Deshayes E; Bonichon-Lamichhane N; Lièvre A; Huguet F; Tlili G; Vendrely V
    J Nucl Med; 2024 Aug; 65(8):1194-1201. PubMed ID: 38936973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
    Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
    Gouriou C; Lemanski C; Pommier P; Le Malicot K; Saint A; Rivin Del Campo E; Evin C; Quero L; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; de la Rocherfordiere A; Drouet F; Vendrely V; Lièvre A
    Br J Cancer; 2024 Mar; 130(5):769-776. PubMed ID: 38184691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
    Vendrely V; Ronchin P; Minsat M; Le Malicot K; Lemanski C; Mirabel X; Etienne PL; Lièvre A; Darut-Jouve A; de la Fouchardière C; Giraud N; Breysacher G; Argo-Leignel D; Thimonnier E; Magné N; Abdelghani MB; Lepage C; Aparicio T;
    Radiother Oncol; 2023 Sep; 186():109742. PubMed ID: 37315583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
    Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
    BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
    Murofushi KN; Itasaka S; Shimokawa M; Murakami Y; Yamamoto T; Nishimura Y; Kudo S; Sakamoto T; Ariga T; Ogo E; Taguchi K; Jingu K; Ogawa K
    J Radiat Res; 2023 Jan; 64(1):154-161. PubMed ID: 36280895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
    Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
    Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
    de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
    Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.
    Neelis KJ; Kip DM; Speetjens FM; van der Linden YM
    Radiat Oncol; 2022 Apr; 17(1):81. PubMed ID: 35443730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
    Gul SK; Tepetam H; Yildiz F; Er I; Oksuz DC; Parvizi M; Ozden AS; Alicikus ZA; Sari SY; Alomari O; Gorken IB
    Clin Colorectal Cancer; 2023 Sep; 22(3):318-326. PubMed ID: 37336706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
    Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
    J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
    Bacci M; Quero L; Barbier E; Parrot L; Juguet F; Pommier P; Bazire L; Etienney I; Baba-Hamed N; Spindler L; François E; Ronchin P; Campo ERD; Lemanski C; Lièvre A; Siproudhis L; Abramowitz L; Lepage C; Vendrely V
    Dig Liver Dis; 2021 Jun; 53(6):776-784. PubMed ID: 33867291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
    Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
    Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
    Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
    Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.